Categories
- Articles (1)
- Past Events (25)
- Press releases (7)
- What's new (12)
During the conference, a multi-stakeholder exchange of ideas identified clear next steps to improve patients’ access to value added medicines:
• Timely approval of value added medicines via streamlined scientific advice processes, fit-for-purpose trial designs and agreed approval pathways with tailor-made incentives for innovation.
• “Next generation guidelines” advised by physicians here.
• A pragmatic value framework that enables access to value added medicines and considers the specific benefits of value added medicines.
• The contribution of digital value added medicines in changing the paradigm of disease management and benefiting patients, healthcare professionals and healthcare systems.
The Value Added Medicines sector group instituted two awards for projects that bring value added solutions to patients.
Winner category “Scientific research/projects led by academics/healthcare professionals/developers that aim to improve existing treatment adherence and/or convenience and/or patients’ preferences and/or demonstrate relevant value added benefits for patients.”
Project “MASK digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice and value-added medicines”,